Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01442363 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease
A Phase 2 study, sponsored by Braintree Laboratories.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01442363 is a Phase 2 study that was terminated before completion, run by Braintree Laboratories. The registered enrollment target is 4 participants.
The verdict
NCT01442363, a Phase 2 study, was terminated before completion, sponsored by Braintree Laboratories.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This randomized, placebo-controlled, parallel, multi-center, double-blind pilot study is designed to determine the effects of BLI-1300 ointment on perianal pain associated with active Perianal Crohn's Disease (PCD).
Interventions
- DRUG placebo
- DRUG BLI-1300 low dose
- DRUG BLI-1300 high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01442363
The ClinicalTrials.gov registry entry for NCT01442363 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Braintree Laboratories, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01442363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01442363 about?
NCT01442363 is a clinical study titled "A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease". This randomized, placebo-controlled, parallel, multi-center, double-blind pilot study is designed to determine the effects of BLI-1300 ointment on perianal pain associated with active Perianal Crohn's Disease (PCD).
What is the current status of trial NCT01442363?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2011-11. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01442363?
The interventions under investigation include: placebo (DRUG), BLI-1300 low dose (DRUG), BLI-1300 high dose (DRUG).
Who is sponsoring clinical trial NCT01442363?
This trial is sponsored by Braintree Laboratories, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.